RFK Jr.’s Priority Plan To Put Peptides In Pharmacies Pushed To White House

A requested policy for adopting an alternative medicine is slotted for approval pending permission from the White House.

Following the sanction of six peptide drugs from the Food and Drug Administration this summer, the Department of Health and Human Services (HHS) submitted an action plan Thursday for peptide medication to President Donald Trump’s Office of Management and Budget (OMB). Getting the peptides approved as compounded drugs in select pharmacies, has been a main priority for Robert F. Kennedy Jr., ever since he took the reins at the HHS.

The American Academy of Peptide Medicine (AAPM) is the listed requestor on the “Interim Access Policy for Compounding Certain Peptides” put forward to the OMB.

Lee Rosebush, chair of the American Academy of Peptide Medicine (AAPM), told the Daily Caller News Foundation in a provided statement that the official posting at OMB is a welcome signal that the process is moving forward, and action could not come soon enough for patients.

“We are encouraged by this progress and see it as an important step toward safe, regulated access,” Rosebush told the DCNF in a statement. “We urge HHS and FDA to place these substances on the interim bulk drug substances lists, which would give patients a safe, legitimate source and help eliminate the black and gray markets. We look forward to the agency’s final decision.”

Founded in 2025, AAPM is a nonprofit academic society “dedicated to advancing the responsible clinical use of peptide therapies,” its website says